Siegfried SFZN.SW
SwitzerlandHealthcare · Drug Manufacturers - Specialty & GenericSIX Swiss Exchange · CHF
100.58 CHF (+45.9%)
12 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Siegfried is a Swiss contract development and manufacturing organization (CDMO) for the pharmaceutical industry, offering production services for active pharmaceutical ingredients and finished dosage forms.
Listed on SIX Swiss Exchange · Symbol SFZN.SW · SWX: SFZN · Currency CHF
Key points
from its scores- ✕Poor share-price trend2.6
- ✕Little or no dividend3.2
- ✕Little competitive advantage4.1
AI analysis
bottom line, main risk, context and newsStable fundamentals and reasonable valuation, but weak cash generation and poor momentum do not warrant initiating a position now.
Siegfried shows solid financial health (ND/EBITDA of 2.59, liquidity of 3.45) and reasonable valuation (P/E 17.63, forward 14.58), but its quality is penalized by negative free cash flow conversion (-43.50%) and growth is moderate (revenue +2.20%). Momentum is weak (11th percentile in 52 weeks).
The negative free cash flow conversion (-43.50%) is the main concrete risk: if it persists, it could limit investment capacity and shareholder returns in the medium term.
Context and risks
Siegfried is a Swiss pharmaceutical CDMO with global exposure. Its business does not depend on commodities or interest rates in a material way, but Switzerland's country risk profile (moderate governance and regulatory) justifies a small downward adjustment in contextual risk.
Is Siegfried stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 25% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 17.6 | 26.7 | −34% |
| EV / EBITDA | 12.2 | 14.5 | −16% |
| Price / book | 3.0 | 4.1 | −26% |
| Price / sales | 2.3 | 3.4 | −34% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.2 out of 10 (median for Healthcare: 4.7).
Average analyst target: 100.58 CHF, +45.9% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 6.4 (sector 6.5), Growth 5.0 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 17.6
- Forward P/E
- 14.6
- EV / EBITDA
- 12.2
- Price / book
- 3.0
- Price / sales
- 2.3
- PEG
- 1.32
- Market cap
- 3.0B CHF
- Enterprise value
- 3.8B CHF
Profitability
- ROE
- 17.0%
- ROA
- 6.4%
- ROIC (approx.)
- 9.9%
- Gross margin
- 27.0%
- Operating margin
- 14.1%
- Net margin
- 12.8%
- Free cash flow
- −137.7M CHF
- FCF yield
- −4.6%
- Cash conversion
- −44%
Solvency
- Total debt
- 925.2M CHF
- Net debt
- 820.0M CHF
- Cash
- 105.2M CHF
- EBITDA
- 316.5M CHF
- Net debt / EBITDA
- 2.59
- Debt / equity
- 93.09
- Current ratio
- 3.45
- Quick ratio
- 1.36
Growth
- Revenue growth
- +2.2%
- Earnings growth
- +4.0%
- EPS (TTM)
- 3.91 CHF
- EPS (forward)
- 4.73 CHF
Dividend
- Dividend yield
- 0.6%
- Payout
- 10.3%
Risk and market
- Beta
- 0.79
- Analyst consensus
- Buy (12)
- Target price
- 100.58 CHF
- 52-week range
- 65.05 – 101.60
Recent news
All SFZN.SW news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Siegfried
Is Siegfried stock cheap or expensive?
On P/E and EV / EBITDA, it trades 25% below the Healthcare median on average. Valuation score: 5.2 out of 10 (median for Healthcare: 4.7). Average analyst target: 100.58 CHF, +45.9% versus the price. This is not investment advice.
What score does Siegfried get on MeridIAn Screener?
It scores 5.0 out of 10, rank 1,711 of 2,130 (better than 19% of the companies analysed). Its strongest category is Risk & Context (6.8) and its weakest, Momentum (2.6). Analysis of 08/10/2026.
What is Siegfried's P/E ratio?
Its P/E is 17.6: the share price equals 17.6 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 14.6.
How much is Siegfried worth on the stock market?
Its market capitalisation is 3.0B CHF and its enterprise value, debt included, is 3.8B CHF.
How much debt does Siegfried have?
Its net debt (debt minus cash) is 820.0M CHF. That is 2.59 times its EBITDA; the Healthcare median is 1.53.
Does Siegfried pay a dividend?
Yes: its dividend yield is 0.58% and it pays out 10% of its earnings.
How has Siegfried stock performed over the last year?
It has fallen 12.7% over the last year, excluding dividends. Over the last 52 weeks it has traded between 65.05 and 101.60 CHF. Past performance does not guarantee future results.
What do analysts think of Siegfried?
12 analysts cover it; their average recommendation is “Buy” and their average target is 100.58 CHF (+45.9% versus the price). It is an estimate, not market data.